SIST EN ISO 10993-10:2023

SLOVENSKI STANDARD
oSIST prEN ISO 10993-10:2020
01-april-2020
Biološko ovrednotenje medicinskih pripomočkov - 10. del: Preskusi
preobčutljivosti kože (ISO/DIS 10993-10:2020)
Biological evaluation of medical devices - Part 10: Tests for skin sensitization (ISO/DIS
10993-10:2020)
Biologische Beurteilung von Medizinprodukten - Teil 10: Prüfungen auf
Hautsensibilisierung (ISO/DIS 10993-10:2020)
Évaluation biologique des dispositifs médicaux -- Partie 10: Essais de sensibilisation
cutanée (ISO/DIS 10993-10:2020)
Ta slovenski standard je istoveten z: prEN ISO 10993-10
ICS:
11.100.20 Biološko ovrednotenje Biological evaluation of
medicinskih pripomočkov medical devices
oSIST prEN ISO 10993-10:2020 en
2003-01.Slovenski inštitut za standardizacijo. Razmnoževanje celote ali delov tega standarda ni dovoljeno.

---------------------- Page: 1 ----------------------
oSIST prEN ISO 10993-10:2020

---------------------- Page: 2 ----------------------
oSIST prEN ISO 10993-10:2020
DRAFT INTERNATIONAL STANDARD
ISO/DIS 10993-10
ISO/TC 194 Secretariat: DIN
Voting begins on: Voting terminates on:
2020-02-14 2020-05-08
Biological evaluation of medical devices —
Part 10:
Tests for skin sensitization
Évaluation biologique des dispositifs médicaux —
Partie 10: Essais de sensibilisation cutanée
ICS: 11.100.20
THIS DOCUMENT IS A DRAFT CIRCULATED
This document is circulated as received from the committee secretariat.
FOR COMMENT AND APPROVAL. IT IS
THEREFORE SUBJECT TO CHANGE AND MAY
NOT BE REFERRED TO AS AN INTERNATIONAL
STANDARD UNTIL PUBLISHED AS SUCH.
IN ADDITION TO THEIR EVALUATION AS
ISO/CEN PARALLEL PROCESSING
BEING ACCEPTABLE FOR INDUSTRIAL,
TECHNOLOGICAL, COMMERCIAL AND
USER PURPOSES, DRAFT INTERNATIONAL
STANDARDS MAY ON OCCASION HAVE TO
BE CONSIDERED IN THE LIGHT OF THEIR
POTENTIAL TO BECOME STANDARDS TO
WHICH REFERENCE MAY BE MADE IN
Reference number
NATIONAL REGULATIONS.
ISO/DIS 10993-10:2020(E)
RECIPIENTS OF THIS DRAFT ARE INVITED
TO SUBMIT, WITH THEIR COMMENTS,
NOTIFICATION OF ANY RELEVANT PATENT
RIGHTS OF WHICH THEY ARE AWARE AND TO
©
PROVIDE SUPPORTING DOCUMENTATION. ISO 2020

---------------------- Page: 3 ----------------------
oSIST prEN ISO 10993-10:2020
ISO/DIS 10993-10:2020(E)

COPYRIGHT PROTECTED DOCUMENT
© ISO 2020
All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may
be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting
on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address
below or ISO’s member body in the country of the requester.
ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Fax: +41 22 749 09 47
Email: copyright@iso.org
Website: www.iso.org
Published in Switzerland
ii © ISO 2020 – All rights reserved

---------------------- Page: 4 ----------------------
oSIST prEN ISO 10993-10:2020
ISO/DIS 10993-10:2020(E)

Contents Page
Foreword .v
Introduction .vi
1 Scope . 1
2 Normative references . 1
3 Terms and definitions . 1
4 General principles — Step-wise approach . 3
5 Pretest considerations . 4
5.1 General . 4
5.2 Types of material. 4
5.2.1 Initial considerations . 4
5.2.2 Ceramics, metals and alloys . 4
5.2.3 Polymers . 4
5.2.4 Biologically derived materials . 4
5.3 Information on chemical composition . 5
5.3.1 General. 5
5.3.2 Existing data sources . 5
6 Skin sensitization tests . 5
6.1 Choice of test methods . 5
6.2 Murine Local Lymph Node Assay (LLNA) . 6
6.2.1 Principle . 6
6.2.2 Test sample preparation. 6
6.2.3 Animals and husbandry . 7
6.2.4 Test procedure . 7
6.2.5 Treatment groups . 8
6.2.6 Determination of cellular proliferation and tissue preparation . 8
6.2.7 Results and interpretation . 9
6.2.8 Test report . 9
6.3 Guinea-pig assays for the detection of skin sensitization . 9
6.3.1 Principle . 9
6.3.2 Choice of test sample concentrations . 9
6.3.3 Induction.10
6.3.4 Challenge .10
6.4 Important factors affecting the outcome of the test .10
6.5 Guinea-pig maximization test (GPMT) .11
6.5.1 Principle .11
6.5.2 Test sample preparation.11
6.5.3 Animals and husbandry .11
6.5.4 Test procedure .11
6.5.5 Observation of animals . .13
6.5.6 Evaluation of results .14
6.5.7 Test report .14
6.6 Closed-patch test (Buehler test) .14
6.6.1 Principle .14
6.6.2 Test sample preparation.14
6.6.3 Animals and husbandry .14
6.6.4 Test procedure .15
6.6.5 Observation of animals . .16
6.6.6 Evaluation of results .16
6.6.7 Test report .16
7 Key factors in interpretation of test results .17
Annex A (normative) Preparation of materials for sensitization testing.18
© ISO 2020 – All rights reserved iii

---------------------- Page: 5 ----------------------
oSIST prEN ISO 10993-10:2020
ISO/DIS 10993-10:2020(E)

Annex B (informative) Method for the preparation of extracts from polymeric test materials .20
Annex C (informative) in vitro tests for skin sensitization .23
Annex D (informative) Background information .36
Annex E (informative) Reference to the general safety and performance requirements .39
Annex ZA (informative) Relationship between this European Standard and the essential
requirements of Directive 93/42/EEC [OJ L 169] aimed to be covered .41
Annex ZB (informative) Relationship between this European Standard and the essential
requirements of Directive 90/385/EEC [OJ L 189] aimed to be covered .43
Annex ZC (informative) Relationship between this European standard and the General
Safety and Performance requirements of Regulation (EU) 2017/745 aimed to be
covered . .44
Bibliography .46
iv © ISO 2020 – All rights reserved

---------------------- Page: 6 ----------------------
oSIST prEN ISO 10993-10:2020
ISO/DIS 10993-10:2020(E)

Foreword
ISO (the International Organization for Standardization) is a worldwide federation of national standards
bodies (ISO member bodies). The work of preparing International Standards is normally carried out
through ISO technical committees. Each member body interested in a subject for which a technical
committee has been established has the right to be represented on that committee. International
organizations, governmental and non-governmental, in liaison with ISO, also take part in the work.
ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of
electrotechnical standardization.
The procedures used to develop this document and those intended for its further maintenance are
described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the
different types of ISO documents should be noted. This document was drafted in accordance with the
editorial rules of the ISO/IEC Directives, Part 2 (see www .iso .org/ directives).
Attention is drawn to the possibility that some of the elements of this document may be the subject of
patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of
any patent rights identified during the development of the document will be in the Introduction and/or
on the ISO list of patent declarations received (see www .iso .org/ patents).
Any trade name used in this document is information given for the convenience of users and does not
constitute an endorsement.
For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and
expressions related to conformity assessment, as well as information about ISO's adherence to the
World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following
URL: www .iso .org/ iso/ foreword .html.
This document was prepared by Technical Committee ISO/TC 194 Biological and clinical evaluation,.
This fourth edition cancels and replaces the third edition (ISO 10993-10:2010), which has been
technically revised.
The main changes compared to the previous edition are as follows:
— This document now contains a description of skin sensitization testing only.
— Annex C on alternative test methods for skin sensitization has been updated.
— The testing for irritation is now described in ISO 10993-23
A list of all parts in the ISO 10993 series can be found on the ISO website.
Any feedback or questions on this document should be directed to the user’s national standards body. A
complete listing of these bodies can be found at www .iso .org/ members .html.
© ISO 2020 – All rights reserved v

---------------------- Page: 7 ----------------------
oSIST prEN ISO 10993-10:2020
ISO/DIS 10993-10:2020(E)

Introduction
This document assesses possible contact hazards from chemicals released from medical devices, which
may produce skin sensitization.
Some materials that are included in medical devices have been tested, and their skin sensitization
potential has been documented. Especially for dental material sensitizing properties were reported see
Reference [50]. Other materials and their chemical components have not been tested and may induce
adverse effects when in contact with human tissue. The manufacturer is thus obliged to evaluate each
device for potential adverse effects prior to marketing.
Traditionally, small animal tests are performed prior to testing on humans to help predict human
response. Since 2015, several in chemico and in vitro assays have been validated and OECD test
[72][76][99]
guidelines released to assess the skin sentization potential of chemicals. These test methods
developed to address a specific key event may not be sufficient to conclude on the presence or absence
of skin sensitisation potential of chemicals and should be considered in the context of integrated
approaches such as IATA, combining them with other complementary information. It should be noted
that the in vitro and in chemico tests for skin sensitization have so far been validated only for neat
chemicals and not for medical device. In order to apply these assays for the testing of skin sensitization
potential of medical devices, further validation for this specific area is essential. . Where appropriate,
the preliminary use of in vitro methods is encouraged for screening purposes prior to animal testing. In
order to reduce the number of animals used, this document presents a step-wise approach, with review
and analysis of test results at each stage. It is intended that, for regulatory submission, sensitization
study/studies be conducted using GLP/ISO 17025 as applicable to the respective country. and comply
with regulations related to animal welfare. Statistical analysis of data is recommended and should be
used whenever appropriate.
This document is intended for use by professionals, appropriately qualified by training and experience,
who are able to interpret its requirements and judge the outcomes of the evaluation for each medical
device, taking into consideration all the factors relevant to the device, its intended use and the current
knowledge of the medical device provided by review of the scientific literature and previous clinical
experience.
The tests included in this document are important tools for the development of safe products, provided
that these are executed and interpreted by trained personnel.
This document is based on numerous standards and guidelines, including OECD Guidelines,
U.S. Pharmacopoeia and the European Pharmacopoeia. It is intended to be the basic document for the
selection and conduct of tests enabling evaluation of dermal sensitization responses relevant to the
safety of medical materials and devices.
vi © ISO 2020 – All rights reserved

---------------------- Page: 8 ----------------------
oSIST prEN ISO 10993-10:2020
DRAFT INTERNATIONAL STANDARD ISO/DIS 10993-10:2020(E)
Biological evaluation of medical devices —
Part 10:
Tests for skin sensitization
1 Scope
This document specifies the procedure for the assessment of medical devices and their constituent
materials with regard to their potential to induce skin sensitization.
This document includes:
— details of in vivo sensitization test procedures;
— key factors for the interpretation of the results.
NOTE Instructions for the preparation of materials specifically in relation to the above tests are given in
Annex A.
2 Normative references
The following documents are referred to in the text in such a way that some or all of their content
constitutes requirements of this document. For dated references, only the edition cited applies. For
undated references, the latest edition of the referenced document (including any amendments) applies.
ISO 10993-1:2018, Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk
management process
ISO 10993-2, Biological evaluation of medical devices — Part 2: Animal welfare requirements
ISO 10993-9, Biological evaluation of medical devices — Part 9: Framework for identification and
quantification of potential degradation products
ISO 10993-12, Biological evaluation of medical devices — Part 12: Sample preparation and reference
materials
ISO 10993-13, Biological evaluation of medical devices — Part 13: Identification and quantification of
degradation products from polymeric medical devices
ISO 10993-14, Biological evaluation of medical devices — Part 14: Identification and quantification of
degradation products from ceramics
ISO 10993-15, Biological evaluation of medical devices — Part 15: Identification and quantification of
degradation products from metals and alloys
ISO 10993-18, Biological evaluation of medical devices — Part 18: Chemical characterization of materials
ISO 14155, Clinical investigation of medical devices for human subjects — Good clinical practice
3 Terms and definitions
For the purposes of this document, the terms and definitions given in ISO 10993-1 and the following apply.
© ISO 2020 – All rights reserved 1

---------------------- Page: 9 ----------------------
oSIST prEN ISO 10993-10:2020
ISO/DIS 10993-10:2020(E)

ISO and IEC maintain terminological databases for use in standardization at the following addresses:
— IEC Electropedia: available at http:// www .electropedia .org/
— ISO Online browsing platform: available at http:// www .iso .org/ obp
3.1
allergen
sensitizer
substance or material that is capable of inducing a specific hypersensitivity reaction upon repeated
contact with that substance or material
3.2
blank
extraction vehicle not containing the test material, retained in a vessel identical to that which holds
the test material and subjected to identical conditions to which the test material is subjected during its
extraction
Note 1 to entry: The purpose of the blank control is to evaluate possible confounding effects due to the extraction
vessel, vehicle and extraction process.
3.3
challenge
elicitation
process following the induction phase, in which the immunological effects of subsequent exposures in
an individual to the inducing material are examined
3.4
erythema
reddening of the skin or mucous membrane
3.5
extract
liquid that results from extraction of the test sample or control
[SOURCE: ISO 10993-12:2012]
3.6
induction
process that leads to the de novo generation of an enhanced state of immunological activity in an
individual, after initial exposure to a specific material
3.7
irritant
agent that produces irritation (see 3.9)
3.8
irritation
localized non-specific inflammatory response to single, repeated or continuous application of a
substance/material
Note 1 to entry: Skin irritation is a reversible reaction and is mainly characterized by local erythema (redness),
swelling, itching, peeling, cracking, scaling etcetera of the skin.
2 © ISO 2020 – All rights reserved

---------------------- Page: 10 ----------------------
oSIST prEN ISO 10993-10:2020
ISO/DIS 10993-10:2020(E)

3.9
negative control
well-characterized material or substance that, when evaluated by a specific test method, demonstrates
the suitability of the procedure to yield a reproducible, appropriately negative, non-reactive or minimal
response in the test system
[SOURCE: SOURCE; ISO 10993-12:2012]
Note 1 to entry: In practice, negative controls include blanks, vehicles/solvents and reference materials.
3.10
oedema
swelling due to abnormal infiltration of fluid into the tissues
3.11
positive control
well-characterized material or substance that, when evaluated by a specific test method, demonstrates
the suitability of the test system to yield a reproducible, appropriately positive or reactive response in
the test system
3.12
skin sensitization
allergic contact dermatitis
immunologically mediated cutaneous reaction to a substance
Note 1 to entry: In the human, the responses can be characterized by pruritis, erythema, oedema, papules,
vesicles, bullae or a combination of these. In other species the reactions can differ and only erythema and oedema
can be seen.
3.13
test material
material, device, device portion or component thereof that is sampled for biological or chemical testing
3.14
test sample
material, device, device portion, component, extract or portion thereof that is subjected to biological or
chemical testing or evaluation
3.15
vehicle
liquid used to moisten, dilute, suspend, extract or dissolve the test substance/material
4 General principles — Step-wise approach
The available methods for testing sensitization were developed specifically to detect skin sensitization
potential. Other types of adverse effects are generally not predicted by these tests. For medical devices
that are used as implants or external communicating devices, intradermal testing is more relevant in
approaching the application.
This document requires a step-wise approach, which shall include one or more of the following:
a) characterization of test material, involving chemical characterization and analysis of the test
sample according to the general principles described in ISO 10993-9, ISO 10993-13, ISO 10993-14,
ISO 10993-15, ISO 10993-17 and ISO 10993-18;
b) literature review, including an evaluation of chemical and physical properties, and information on
the sensitization potential of any product constituent as well as structurally-related chemicals and
materials;
c) in accordance with ISO 10993-2, in vitro tests in preference to in vivo tests shall be considered, and
replacement of the latter as new in vitro tests are scientifically validated and become reasonably
© ISO 2020 – All rights reserved 3

---------------------- Page: 11 ----------------------
oSIST prEN ISO 10993-10:2020
ISO/DIS 10993-10:2020(E)

and practicably available. There are currently a number of internationally validated and accepted
in vitro tests to detect the skin sentization potential of chemicals; However, none of these tests has
been qualified for use with medical devices.
d) in vivo animal tests
NOTE 1 Sensitization potential of medical device extracts can at the moment only be determined by an
in vivo assay. This can be accomplished by using the local lymph node assay (LLNA) in mice, the occluded
patch test in guinea-pigs or the guinea-pig maximization test (GPMT).
NOTE 2 In vivo animal tests are appropriate when test materials cannot be characterized and risk
assessments cannot be undertaken using information obtained by the means set out in a), b) and c).
e) Clinical studies, in accordance with ISO 14155 and ethics principles, shall not be performed before
the results of the other evaluations in a) to e) are known.
5 Pretest considerations
5.1 General
It is important to emphasise that pretest considerations may result in the conclusion that testing for
sensitization is not necessary.
The requirements given in ISO 10993-1:2018, Clause 5, and the following apply.
Non-sterile samples shall be investigated by topical investigation only, as the possibility of microbial
contamination of the test sample could confound the final assay interpretation. In cases where
the sterility of a test sample cannot be guaranteed, but the sample is still considered to be non-
contaminated, intradermal administration may be justified.
5.2 Types of material
5.2.1 Initial considerations
It shall be taken into consideration that during manufacture and assembly of medical devices, additional
chemical components may be used as processing aids, e.g. lubricants or mould-release agents. In addition
to the chemical components of the starting material and manufacturing process aids, adhesive/solvent
residues from assembly and also sterilant residues or reaction products resulting from the sterilization
process may be present in a finished product. Whether these components pose a health hazard/risk
depends on the leaching or degradation characteristics of the finished products. These components
shall be taken into account for their potential sensitization activity.
5.2.2 Ceramics, metals and alloys
These materials are normally less complex than polymers and biologically derived materials in terms of
the number of chemical constituents.
5.2.3 Polymers
These materials are normally chemically more complex than those in 5.2.2 in terms of composition. A
number of reaction products/impurities/additives/residual catalyst can be present and the degree or
extent of polymerization can vary.
5.2.4 Biologically derived materials
These materials are inherently complex in their composition. They often also contain process
residues, e.g. cross-linke
...